Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radioactive therapy targets Hard-to-Treat prostate cancer

NCT ID NCT07621692

Recruiting now Disease control Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new radioactive drug (161Tb-PSMA-I&T) in 12 Taiwanese men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The drug seeks out prostate cancer cells and delivers targeted radiation. The main goal is to check safety and find the right dose, not to cure the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Taiwan University Cancer Center

    RECRUITING

    Taipei, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Taiwan University Hospital

    RECRUITING

    Taipei, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••